Skip to main content
Erschienen in: Targeted Oncology 4/2017

14.07.2017 | Adis Drug Evaluation

Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer

verfasst von: Yvette N. Lamb, Lesley J. Scott

Erschienen in: Targeted Oncology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Osimertinib (Tagrisso™) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets EGFR TKI-sensitizing mutations and, crucially, the T790M mutation that often underlies acquired resistance to EGFR TKI therapy. Osimertinib has been approved in numerous countries for use in patients with T790M-positive advanced NSCLC. In the pivotal, international AURA3 trial in patients with T790M-positive advanced NSCLC who had disease progression after EGFR TKI therapy, osimertinib treatment significantly prolonged progression-free survival (PFS; primary endpoint) compared with platinum-pemetrexed therapy at the time of the primary analysis. PFS results were consistent across predefined subgroups of patients, including those with CNS metastases at baseline. There was no difference between treatment groups in overall survival at 26% maturity. Objective response rates (ORRs) and patient-reported outcomes for prespecified symptoms were also significantly improved with osimertinib relative to platinum-pemetrexed, with CNS ORRs in patients with CNS metastases more than twofold higher in the osimertinib than in the platinum-pemetrexed group. Osimertinib had a manageable tolerability profile, with relatively few patients permanently discontinuing treatment because of adverse events (AEs). With limited treatment options available in this setting, osimertinib is an important option in adult patients with advanced EGFR T790M-positive NSCLC.
Literatur
2.
3.
Zurück zum Zitat Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.CrossRefPubMedPubMedCentral Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015;16:e447–59.CrossRefPubMed Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015;16:e447–59.CrossRefPubMed
5.
6.
Zurück zum Zitat Novello S, Barlesi F, Califani R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v1–v27.CrossRefPubMed Novello S, Barlesi F, Califani R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v1–v27.CrossRefPubMed
7.
Zurück zum Zitat Khozin S, Weinstock C, Blumenthal GM, et al. Osimertinib for the treatment of metastatic EGFR T970M mutation-positive non-small cell lung cancer. Clin Cancer Res. 2016;23(9):2131–5. Khozin S, Weinstock C, Blumenthal GM, et al. Osimertinib for the treatment of metastatic EGFR T970M mutation-positive non-small cell lung cancer. Clin Cancer Res. 2016;23(9):2131–5.
8.
Zurück zum Zitat Pirker R. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2016;28(2):115–21.CrossRefPubMed Pirker R. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2016;28(2):115–21.CrossRefPubMed
9.
Zurück zum Zitat AstraZeneca. Tagrisso approved in China as first-in-class treatment for EGFR T790M mutation-positive metastatic non-small cell lung cancer [media release]. 2017. http://www.astrazeneca.com/. Accessed 28 Jun 2017. AstraZeneca. Tagrisso approved in China as first-in-class treatment for EGFR T790M mutation-positive metastatic non-small cell lung cancer [media release]. 2017. http://​www.​astrazeneca.​com/. Accessed 28 Jun 2017.
11.
13.
Zurück zum Zitat Oxnard GR, Thress KS, Alden RS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non–small-cell lung cancer. J Clin Oncol. 2016;34(28):3375–82.CrossRefPubMed Oxnard GR, Thress KS, Alden RS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non–small-cell lung cancer. J Clin Oncol. 2016;34(28):3375–82.CrossRefPubMed
15.
Zurück zum Zitat Cross DAE, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046–61.CrossRefPubMedPubMedCentral Cross DAE, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046–61.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Ballard P, Yates JWT, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130–40.CrossRefPubMed Ballard P, Yates JWT, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130–40.CrossRefPubMed
17.
Zurück zum Zitat Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2016;376:629–40.CrossRefPubMed Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2016;376:629–40.CrossRefPubMed
18.
Zurück zum Zitat Yang JC, Ahn M-J, Kim D-W, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35(12):1288–96.CrossRefPubMed Yang JC, Ahn M-J, Kim D-W, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35(12):1288–96.CrossRefPubMed
19.
Zurück zum Zitat Goss G, Tsai C-M, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17(12):1643–52.CrossRefPubMed Goss G, Tsai C-M, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17(12):1643–52.CrossRefPubMed
20.
Zurück zum Zitat Jänne PA, Yang JCH, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–99.CrossRefPubMed Jänne PA, Yang JCH, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–99.CrossRefPubMed
21.
Zurück zum Zitat Brown K, Comisar C, Witjes H, et al. Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer. Br J Clin Pharmacol. 2017;83(6):1216–26.CrossRefPubMed Brown K, Comisar C, Witjes H, et al. Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer. Br J Clin Pharmacol. 2017;83(6):1216–26.CrossRefPubMed
22.
Zurück zum Zitat Planchard D, Loriot Y, Andre F, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol. 2015;26(10):2073–8.CrossRefPubMed Planchard D, Loriot Y, Andre F, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol. 2015;26(10):2073–8.CrossRefPubMed
23.
Zurück zum Zitat Kim TM, Song A, Kim DW, et al. Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor. J Thorac Oncol. 2015;10(12):1736–44.CrossRefPubMed Kim TM, Song A, Kim DW, et al. Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor. J Thorac Oncol. 2015;10(12):1736–44.CrossRefPubMed
24.
Zurück zum Zitat Ortiz-Cuaran S, Scheffler M, Plenker D, et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clin Cancer Res. 2016;22(19):4837–47.CrossRefPubMed Ortiz-Cuaran S, Scheffler M, Plenker D, et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clin Cancer Res. 2016;22(19):4837–47.CrossRefPubMed
25.
Zurück zum Zitat Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harbouring EGFR T790M. Nat Med. 2015;21(6):560–2.CrossRefPubMedPubMedCentral Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harbouring EGFR T790M. Nat Med. 2015;21(6):560–2.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Planchard D, Brown KH, Kim D-W, et al. Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemother Pharmacol. 2016;77(4):767–76.CrossRefPubMed Planchard D, Brown KH, Kim D-W, et al. Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemother Pharmacol. 2016;77(4):767–76.CrossRefPubMed
27.
Zurück zum Zitat Vishwanathan K, Dickinson PA, Bui K, et al. Effect of food and gastric pH modifiers on the pharmacokinetics of AZD9291 [abstract no. B153]. Mol Cancer Ther. 2015;14(12 Suppl 2):B153.CrossRef Vishwanathan K, Dickinson PA, Bui K, et al. Effect of food and gastric pH modifiers on the pharmacokinetics of AZD9291 [abstract no. B153]. Mol Cancer Ther. 2015;14(12 Suppl 2):B153.CrossRef
28.
Zurück zum Zitat Kim D, Yang J, Cross D, et al. Preclinical evidence and clinical cases of AZD9291 activity in EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases (BM) [abstract no. 456P]. Ann Oncol. 2014;25(Suppl 4):iv152.CrossRef Kim D, Yang J, Cross D, et al. Preclinical evidence and clinical cases of AZD9291 activity in EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases (BM) [abstract no. 456P]. Ann Oncol. 2014;25(Suppl 4):iv152.CrossRef
29.
Zurück zum Zitat Ahn MJ, Tsai CM, Yang JCH, et al. AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: data from phase II studies [abstract no. 3083]. Eur J Cancer. 2015;51(Suppl 3):S625–6.CrossRef Ahn MJ, Tsai CM, Yang JCH, et al. AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: data from phase II studies [abstract no. 3083]. Eur J Cancer. 2015;51(Suppl 3):S625–6.CrossRef
30.
Zurück zum Zitat Dickinson PA, Cantarini MV, Collier J, et al. Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor. Drug Metab Dispos. 2016;44(8):1201–12.CrossRefPubMed Dickinson PA, Cantarini MV, Collier J, et al. Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor. Drug Metab Dispos. 2016;44(8):1201–12.CrossRefPubMed
Metadaten
Titel
Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer
verfasst von
Yvette N. Lamb
Lesley J. Scott
Publikationsdatum
14.07.2017
Verlag
Springer International Publishing
Erschienen in
Targeted Oncology / Ausgabe 4/2017
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-017-0519-0

Weitere Artikel der Ausgabe 4/2017

Targeted Oncology 4/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.